Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 51.30M, and currently, short sellers hold a 32.13% ratio of that floaft. The average trading volume of SPRY on March 06, 2025 was 1.32M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY) has experienced a rise in its stock price by 3.43 compared to its previous closing price of 10.51. However, the company has seen a gain of 6.26% in its stock price over the last five trading days. globenewswire.com reported 2025-03-05 that neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children
SPRY’s Market Performance
SPRY’s stock has risen by 6.26% in the past week, with a monthly drop of -11.70% and a quarterly drop of -25.09%. The volatility ratio for the week is 6.21% while the volatility levels for the last 30 days are 6.28% for ARS Pharmaceuticals Inc The simple moving average for the last 20 days is -4.22% for SPRY’s stock, with a simple moving average of -10.26% for the last 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Oppenheimer repeating the rating for SPRY by listing it as a “Outperform.” The predicted price for SPRY in the upcoming period, according to Oppenheimer is $40 based on the research report published on February 10, 2025 of the current year 2025.
Raymond James gave a rating of “Strong Buy” to SPRY, setting the target price at $22 in the report published on August 13th of the previous year.
SPRY Trading at -8.25% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.27% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 6.21%, as shares sank -13.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.82% lower at present.
During the last 5 trading sessions, SPRY rose by +6.26%, which changed the moving average for the period of 200-days by +22.41% in comparison to the 20-day moving average, which settled at $11.35. In addition, ARS Pharmaceuticals Inc saw 3.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who proposed sale 50,000 shares at the price of $11.00 back on Mar 05 ’25. After this action, Shawver Laura now owns shares of ARS Pharmaceuticals Inc, valued at $550,000 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc, sale 50,000 shares at $12.31 during a trade that took place back on Feb 03 ’25, which means that Shawver Laura is holding 210,346 shares at $615,565 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -23.84 for the present operating margin
- 0.94 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -19.35. The total capital return value is set at -0.3. Equity return is now at value -22.41, with -21.07 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -449.62. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -16.13.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 400.65. The receivables turnover for the company is 3.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.54.
Conclusion
In a nutshell, ARS Pharmaceuticals Inc (SPRY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
